Pawd develops a veterinarian-formulated, natural liquid supplement aimed at reducing canine anxiety without sedation. Launched in March 2024, the company already counts more than 900 active monthly subscribers and is targeting 10,000 within the next year. Founders Archie Wilson and Rory Hanna identified the market gap after Hanna’s family dog displayed anxiety symptoms and partnered with animal nutritionists and vets to create the product. The startup intends to channel rigorous formulation and responsible manufacturing practices as it scales. Looking ahead, Pawd plans a U.S. market entry and is forecasting profitability by Q3 2026. Proceeds from its latest funding will support marketing expansion, including hiring a part-time CMO and broad social media and influencer campaigns, while additional capital would fund growth tests across acquisition and retention channels.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026